GlaxoSmithKline PLC Publication of AGM Notice (2920H)
March 24 2020 - 3:00AM
UK Regulatory
TIDMGSK
RNS Number : 2920H
GlaxoSmithKline PLC
23 March 2020
GlaxoSmithKline plc
(the 'Company')
Publication of Notice of Annual General Meeting 2020
The Company will shortly publish on its website (
www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/
) the Notice of Annual General Meeting 2020 (the '2020 AGM Notice')
which will be distributed to shareholders shortly.
The Company's Annual General Meeting ('AGM') is to be held on
Wednesday 6 May 2020 at 2.30pm at the Sofitel London Heathrow,
Terminal 5, London Heathrow Airport, TW6 2GD .
The evolving COVID-19 situation and the related Government
guidelines will clearly impact the ability of shareholders to
attend our AGM. In normal circumstances, the Board values greatly
the opportunity to meet shareholders in person. However, it
supports fully the recent Government advice for people to avoid
both mass gatherings and all non-essential travel and social
contact and notes that some or all of the recommendations contained
in the Government's guidelines could become mandatory at any time.
On this basis, the Board has concluded that it is appropriate to
strongly urge shareholders not to attend the AGM in person this
year as to do so would be inconsistent with current Government
guidelines relative to COVID-19 and, instead, to submit proxy
votes. These Government guidelines can be found at
www.gov.uk/coronavirus .
Our AGM format this year will be purely functional in format to
comply with the relevant legal requirements. There will be no
presentations or exhibitions. No refreshments or product gift bags
will be provided and any Board members attending the meeting will
not meet with shareholders individually.
Our mission is to do more to help people feel better and live
longer and to that end we seek your assistance to protect our
shareholders, employees and the Board and as a result to enable the
Company to continue to focus on providing healthcare to patients in
need.
Instead of attending this year's AGM, shareholders are asked to
exercise their votes by submitting their proxy electronically or by
post, as explained below. In addition, should a shareholder have a
question that they would have raised at the meeting, we ask that
instead of attending the meeting they send it by email to
company.secretary@gsk.com . Answers to questions will be published
on our website following the AGM.
The situation in relation to COVID-19 continues to develop and
the Company will update shareholders on arrangements for the AGM
through its website at
www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/
. Shareholders are advised to check the Company's website for
updates or to contact the Company's registrar, Equiniti. Equiniti's
contact details can be found on page 18 of the 2020 AGM Notice.
Voting
Shareholders are asked to vote on the AGM resolutions by lodging
a proxy so that it is not necessary to be physically present. They
are encouraged to appoint the "Chairman of the meeting" to vote on
their behalf. This can be done by completing a Proxy Form or
submitting proxy instructions electronically. Proxy instructions
must be received by Equiniti by 2.30pm on Monday 4 May 2020.
Participants in the GSK Corporate Sponsored Nominee Service can
exercise their voting rights through Equiniti by completing a Form
of Direction or submitting voting instructions electronically.
Instructions must be received by Equiniti by 5.00pm on Wednesday 29
April 2020.
Any holder of the Company's shares through a nominee service
should contact their nominee service provider regarding the process
for appointing a proxy to vote on their behalf. The deadline for
this is likely to be before Monday 4 May 2020.
Further details on the appointment of proxies can be found on
pages 17 to 19 of the 2020 AGM Notice.
The Board would like to take this opportunity to thank all
shareholders for their continued support and understanding in these
exceptional circumstances and wish them well during this time as we
all navigate the implications of COVID-19. We will return to full
shareholder engagement as soon as feasible.
Please see our website for details on how the Company is
contributing specifically with regard to COVID-19.
In compliance with Listing Rule 9.6.1R of the UK Financial
Conduct Authority, the 2020 AGM Notice will be submitted to the UK
Listing Authority and will, in due course, be available for
inspection at www.morningstar.co.uk/uk/NSM .
V A Whyte
Company Secretary
23 March 2020
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit http://www.gsk.com
.
GSK enquiries:
Global Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
Tim Foley +44 (0) 20 8047 (London)
5502
US Media enquiries: Sarah Spencer +1 215 751 3335 (Philadelphia)
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Danielle Smith +44 (0) 20 8047 (London)
0932
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Principal risks and uncertainties' in the Company's Annual Report
on Form 20-F for 2019. GSK also refers investors to the cautionary
statement on the inside back cover of the Annual Report 2019.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAFFFLIVTIVFII
(END) Dow Jones Newswires
March 24, 2020 03:00 ET (07:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024